Publication: The effectiveness of cucurbitacin B in BRCA1 defective breast cancer cells
Issued Date
2013-02
Resource Type
Language
eng
ISSN
1932-6203
Rights
Mahidol University
Rights Holder(s)
PLoS ONE
Bibliographic Citation
Plos One. Vol.8, No.2 (2013), 1-14
Suggested Citation
Moltira Promkan, Sumana Dakeng, Subhas Chakrabarty, Oliver Bögler, Pimpicha Patmasiriwat The effectiveness of cucurbitacin B in BRCA1 defective breast cancer cells. Plos One. Vol.8, No.2 (2013), 1-14. doi:10.1371/journal.pone.0055732 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/2103
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The effectiveness of cucurbitacin B in BRCA1 defective breast cancer cells
Other Contributor(s)
Abstract
Cucurbitacin B (CuB) is one of the potential agents for long term anticancer chemoprevention. Cumulative evidences has shown that cucurbitacin B provides potent cellular biological activities such as hepatoprotective, anti-inflammatory and antimicrobial effects, but the precise mechanism of this agent is not clearly understood. We examine the biological effects on cancer cells of cucurbitacin B extracted from a Thai herb, Trichosanthes cucumerina L. The wild type (wt) BRCA1, mutant BRCA1, BRCA1 knocked-down and BRCA1 overexpressed breast cancer cells were treated with the cucurbitacin B and determined for the inhibitory effects on the cell proliferation, migration, invasion, anchorage-independent growth. The gene expressions in the treated cells were analyzed for p21/Waf1, p27Kip1 and survivin. Our previous study revealed that loss of BRCA1 expression leads to an increase in survivin expression, which is responsible for a reduction in sensitivity to paclitaxel. In this work, we showed that cucurbitacin B obviously inhibited knocked-down and mutant BRCA1 breast cancer cells rather than the wild type BRCA1 breast cancer cells in regards to the cellular proliferation, migration, invasion and anchorage-independent growth. Furthermore, forcing the cells to overexpress wild type BRCA1 significantly reduced effectiveness of cucurbitacin B on growth inhibition of the endogenous mutant BRCA1 cells. Interestingly, cucurbitacin B promotes the expression of p21/Waf1 and p27Kip1 but inhibit the expression of survivin. We suggest that survivin could be an important target of cucurbitacin B in BRCA1 defective breast cancer cells.